Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roivant Sciences
Biotech
Roivant unveils new ‘vant’ to advance Bayer hypertension med
Matt Gline is back with a new ‘vant,’ after the Roivant CEO paid Bayer $14 million upfront for the rights to a phase 2-ready hypertension drug.
James Waldron
Sep 10, 2024 7:57am
Top 10 smartest deals in biopharma
Jun 24, 2024 6:00am
Lokavant launches AI solution for real-time trial optimization
Jun 11, 2024 3:45pm
Roivant's Hemavant bet winds down after cutting ex-Eisai drug
Feb 13, 2024 2:01pm
BMS signs $674M biobucks pact with VantAI for molecular glues
Feb 13, 2024 11:00am
Genevant secures $114M deal with Tome to develop liver therapy
Jan 16, 2024 10:11am